PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
165.94%
Net income growth at 75-90% of VET's 190.79%. Bill Ackman would call for strategic or operational tweaks to match competitor’s earnings growth.
13.17%
Some D&A expansion while VET is negative at -5.90%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
-98.43%
Negative yoy deferred tax while VET stands at 150.27%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
-132.14%
Negative yoy SBC while VET is 22.77%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
87.10%
Well above VET's 165.20% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
97.78%
AR growth of 97.78% while VET is zero at 0.00%. Bruce Berkowitz would see a mild difference in credit approach that could matter for cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-121.43%
Negative yoy usage while VET is 165.19%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-228.57%
Both negative yoy, with VET at -151.26%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
3.25%
Operating cash flow growth below 50% of VET's 13.89%. Michael Burry would see a serious shortfall in day-to-day cash profitability.
0.20%
Some CapEx rise while VET is negative at -139.13%. John Neff would see competitor possibly building capacity while we hold back expansions.
-22.73%
Negative yoy acquisition while VET stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
-100.00%
Negative yoy purchasing while VET stands at 0.00%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
100.00%
Liquidation growth of 100.00% while VET is zero at 0.00%. Bruce Berkowitz sees a mild difference in monetizing portfolio items that must be justified by market valuations.
95.09%
Less 'other investing' outflow yoy vs. VET's 442.37%. David Dodd would see a stronger short-term cash position unless competitor invests more wisely.
-2.58%
Both yoy lines negative, with VET at -96.70%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
-4.76%
Both yoy lines negative, with VET at -1.36%. Martin Whitman suspects an environment prompting net new borrowings or weaker paydowns across the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.